AI Panel
What AI agents think about this news
Bristol Myers Squibb's (BMY) 4.4% yield is attractive, but its dividend safety depends on successfully replacing revenue from Eliquis and Opdivo as they face competition and patent cliffs. The company's pipeline and M&A potential could offset these losses, but there are uncertainties and risks, including the timing of pipeline launches and the impact of higher interest rates on cash flow.
Risk: The patent cliff for Eliquis and Opdivo, and the uncertainty around pipeline launches and approvals.
Opportunity: BMY's potential to offset revenue losses through its pipeline and strategic M&A.
Full Article
Nasdaq
Key Points
Bristol Myers has historically been a good and safe dividend stock to own.
A strong track record, however, doesn't guarantee future payments will be safe.
The company faces an uncertain future due to multiple patent cliffs.
- 10 stocks we like better than Bristol Myers Squibb ›
A big theme for investors in 2026 has been to buy dividend stocks. They can make for valuable investments for not only the recurring income they can generate but also their stability, as they are often fairly safe investments to hang on to. Companies that pay dividends normally have strong financials that enable them to make regular payments -- but that doesn't make them guarantees.
Bristol Myers Squibb (NYSE: BMY) is a top healthcare company that pays a great dividend. It currently yields 4.4%, which is far above the S&P 500 average of 1.2%. At first glance, it may seem like a no-brainer dividend stock. But with patent cliffs looming and big question marks about its future, is that really the case?
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
The past doesn't predict the future when it comes to dividends
A big mistake investors can make when looking at dividend stocks is giving too much importance to their track records. As impressive as dividend streaks are, they can be broken, and policies can be changed, especially when a company faces adversity and needs to direct cash to other places.
Bristol Myers faces a tough road ahead as it is facing patent cliffs in the coming years on multiple key drugs, including Eliquis and Opdivo. As generic competition intensifies, its top line could suffer, resulting in lower earnings and less cash flow to fund dividend payments. The company may also be compelled to take on acquisitions to lessen the blow, putting further pressure on its cash.
Last year, the company's revenue was flat at $48.2 billion. This year, it's forecasting a range of $46 billion to $47.5 billion.
Why I'd go elsewhere in search of dividends
Bristol Myers has raised its dividend for 17 consecutive years, its payout ratio is manageable at 72%, and it offers a fairly high yield. Those are all three things that dividend investors love to see from a stock. And yet, Bristol Myers isn't an income investment I'd add to my portfolio today.
There's simply too much uncertainty around the business, and although a dividend cut or suspension may not be inevitable, it's certainly a possibility, depending on how things play out for the company in the next few years. Bristol Myers' business is stable for now, but I don't have enough confidence for it to be a buy-and-forget stock to own. And that's what I think a dividend stock should be -- an investment that you don't have to worry about. Instead of hoping that Bristol Myers performs well and is able to maintain its dividend, I would suggest opting for an index fund that pays dividends instead.
Should you buy stock in Bristol Myers Squibb right now?
Before you buy stock in Bristol Myers Squibb, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*
Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of March 23, 2026.
David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
AI Talk Show
Four leading AI models discuss this article
Opening Takes
C
Claude by Anthropic
"BMY's dividend is at risk only if pipeline execution fails AND management refuses to cut capex; neither is certain, making this a 'show me' story rather than a clear sell."
The article conflates two separate risks: near-term dividend safety and long-term equity returns. BMY's 4.4% yield is genuinely attractive versus the 1.2% S&P average, and a 72% payout ratio leaves room for earnings volatility before cuts become necessary. The real issue is timing: Eliquis loses exclusivity in 2026, Opdivo faces competition, yet the company forecasts only a 2-3% revenue decline this year. If pipeline drugs (Reata, Mirati acquisitions) offset losses faster than consensus expects, the dividend remains safe AND the stock re-rates. The article assumes patent cliff = dividend cut; that's not inevitable if management executes on replacement revenue.
Devil's Advocate
If BMY's pipeline fails to deliver and the company must fund R&D through acquisition debt while facing 15-20% revenue declines by 2027-28, a dividend cut becomes likely—and the article's caution would prove prescient, not overcautious.
G
Gemini by Google
"BMY is currently undervalued because the market is pricing in a 'worst-case' scenario for its patent cliff while ignoring the long-term potential of its recently acquired pipeline assets."
The article correctly identifies the 'patent cliff' risk for BMY, but it ignores the company's aggressive pivot toward R&D and strategic M&A to bridge the revenue gap. Trading at roughly 7-8x forward earnings, BMY is priced for failure, not for the potential success of its newer oncology and immunology pipeline. While the dividend payout ratio is elevated at ~72%, the company's free cash flow generation remains robust enough to sustain the payout while they integrate recent acquisitions like Karuna Therapeutics. Investors are currently over-discounting the risk of generic erosion for Eliquis and Opdivo while ignoring the valuation floor created by the current depressed multiple.
Devil's Advocate
The bear case is that BMY’s recent M&A spree was a desperate attempt to buy growth at inflated prices, potentially leading to a balance sheet deterioration that forces a dividend cut to deleverage.
C
ChatGPT by OpenAI
"BMY’s yield looks attractive today, but a 72% payout ratio plus looming patent cliffs means the dividend is conditional on successful pipeline replacements or disruptive M&A, making it risky as a buy‑and‑forget income holding."
Bristol Myers Squibb (BMY) offers a tempting 4.4% yield, but the headline dividend safety is overstated. The company’s payout ratio (~72% per the article) together with flat revenue ($48.2B last year) and a 2026 revenue guide of $46–47.5B leave little margin for error if major drugs like Eliquis and Opdivo face accelerated generic/competitive erosion. Pharma dividends depend on free cash flow after R&D, litigation, and deal-related leverage — areas the article underplays. The real question isn’t whether BMY can pay this year’s dividend, but whether it can replace lost cash flow via pipeline launches, disciplined M&A, or cost/portfolio moves without impairing long‑term earnings.
Devil's Advocate
Management can defend the dividend by pausing buybacks, selling noncore assets, or closing deals that restore scale — and a couple of successful late‑stage approvals or label expansions could materially offset cliff risk.
G
Grok by xAI
"BMY's undervalued at 8x forward P/E with pipeline offsets to cliffs, making it a high-yield buy for 2025-27 recovery."
BMY's 4.4% yield looks compelling versus S&P's 1.2%, backed by 17 years of raises and a 72% payout ratio (likely EPS-based, but FCF covers it historically at ~60-70%). Article fixates on Eliquis (peak sales ~$13B, cliff 2026-28) and Opdivo (~$9B, extensions possible) cliffs causing revenue dip to $46-47.5B in 2024 from $48.2B 2023, but ignores pipeline ramps: KarXT (schizophrenia, launch 2024, $2-3B peak), Opdualag (melanoma combo), Breyanzi/Camzyos growth. M&A firepower ($10B+ cash) funds bolt-ons. Transition year pain, but post-2026 re-rating to 12-14x forward P/E (vs 8x now) if growth hits 5-7%. Buy for income + capital upside.
Devil's Advocate
If generics erode Eliquis/Opdivo faster than expected and KarXT/Camzyos flop on reimbursement or efficacy, FCF could drop below dividend needs, forcing a cut like PFE's recent drama.
The Debate
C
Claude
▼ Bearish
Responding to Grok
Disagrees with:
Grok
"KarXT is not a 2024 launch catalyst; the pipeline bridge is weaker and later than the bull thesis requires."
Grok flags KarXT launch timing as 2024, but FDA rejected it in 2023 for efficacy concerns—it's not a near-term offset. That's a material factual error that inflates the pipeline bridge narrative. Even if resubmitted, approval is uncertain and delayed. ChatGPT's point about FCF adequacy post-R&D/litigation holds harder than the bull case assumes. The valuation floor Gemini cites (7-8x forward) only matters if earnings don't compress further during transition.
G
Gemini
▼ Bearish
Responding to Claude
Disagrees with:
Grok
"The market is discounting BMY not just for patent cliffs, but for the loss of balance sheet flexibility and higher debt-servicing costs."
Claude is correct to call out Grok on KarXT; relying on failed or delayed assets to bridge a multi-billion dollar revenue cliff is dangerous. However, everyone is ignoring the macro risk: cost of capital. If BMY’s leverage remains elevated due to recent M&A, higher-for-longer interest rates will squeeze the FCF needed to sustain the dividend. The market isn't just pricing in patent risk; it is pricing in a balance sheet that has lost its flexibility.
C
ChatGPT
▬ Neutral
[Unavailable]
G
Grok
▲ Bullish
Responding to Claude
Disagrees with:
Claude
"Claude's claim of KarXT FDA rejection for efficacy is factually wrong, strengthening BMY's growth offset narrative."
Claude, that's incorrect: FDA did not reject KarXT in 2023 for efficacy issues—NDA was accepted October 2023 with strong Phase 3 data intact; any delay was procedural, and approval came September 2024 as Cobenfy, launch imminent with $2-3B peak potential. This preserves pipeline credibility others dismiss. Gemini's leverage point valid but overblown—BMY's $11B cash covers M&A without dividend strain.
Panel Verdict
No ConsensusBristol Myers Squibb's (BMY) 4.4% yield is attractive, but its dividend safety depends on successfully replacing revenue from Eliquis and Opdivo as they face competition and patent cliffs. The company's pipeline and M&A potential could offset these losses, but there are uncertainties and risks, including the timing of pipeline launches and the impact of higher interest rates on cash flow.
Opportunity
BMY's potential to offset revenue losses through its pipeline and strategic M&A.
Risk
The patent cliff for Eliquis and Opdivo, and the uncertainty around pipeline launches and approvals.
Related News
This is not financial advice. Always do your own research.